Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SchizOMICS
2024-516768-28-00Phase 4Authorised
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Dec 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole, paliperidone palmitate, 5-hydroxytryptophan and risperidone in schizophrenia, schizophreniform disorder, schizoaffective disorder and 2 more (2 arms), sponsored by Centro de Investigación Biomédica en Red. Primary endpoint: Therapeutic response to aripiprazole or paliperidone. Planned start Dec 2024; status: authorised.
02
Drugs
aripiprazolepaliperidone palmitate5-hydroxytryptophanrisperidone
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorderbrief psychotic disorder (BPD)Unspecified psychosis
Beyond the preview
Go deeper on 2024-516768-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516768-28-00.